Q3 2019 13F Holders as of 9/30/2019
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
147M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
71.2M
-
Shares change
-
-116K
-
Total reported value, excl. options
-
$1.09B
-
Value change
-
-$4.83M
-
Put/Call ratio
-
1.75
-
Number of buys
-
50
-
Number of sells
-
-38
-
Price
-
$15.32
Significant Holders of Denali Therapeutics Inc. - COMMON STOCK (DNLI) as of Q3 2019
128 filings reported holding DNLI - Denali Therapeutics Inc. - COMMON STOCK as of Q3 2019.
Denali Therapeutics Inc. - COMMON STOCK (DNLI) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 71.2M shares
of 147M outstanding shares and own 48.34% of the company stock.
Largest 10 shareholders include Crestline Management, LP (19.5M shares), Flagship Pioneering Inc. (8.01M shares), BAILLIE GIFFORD & CO (7.36M shares), VANGUARD GROUP INC (6.1M shares), BlackRock Inc. (5.25M shares), FMR LLC (4.91M shares), Temasek Holdings (Private) Ltd (4.41M shares), STATE STREET CORP (1.59M shares), LORD, ABBETT & CO. LLC (1.17M shares), and BAMCO INC /NY/ (985K shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.